HOME >> MEDICINE >> NEWS
Statement on the findings of the Women's Health Study

The Women's Health Study is the first large clinical trial to study the use of low-dose aspirin to prevent heart attack and stroke in women. The 10-year randomized, double-blind, placebo-controlled study was conducted among nearly 40,000 healthy women age 45 and older. Although studies have shown that low-dose aspirin reduces the risk of a first heart attack in men, there have been few such studies in women. The study was supported by the National Institutes of Health's National Heart, Lung, and Blood Institute and the National Cancer Institute.

The Women's Health Study found that aspirin did not prevent first heart attacks or death from cardiovascular causes in women. Low-dose aspirin (100 mg on alternate days) lowered the incidence of a first major cardiovascular event (nonfatal heart attack, non-fatal stroke, or death from cardiovascular causes) by 9 percent. This was not statistically significant. Stroke was 17 percent lower in the aspirin group, a statistically significant difference. The findings of the study will be presented at the American College of Cardiology's (ACC) annual meeting in Orlando, FL and also published online in The New England Journal of Medicine March 7, 2005 and in print in the March 31 issue.

The greatest benefit appeared to be in women 65 and older. In this sub-group, low-dose aspirin reduced the risk of major cardiovascular events by 26 percent. However, the benefits of low-dose aspirin therapy must be weighed against the risk of an increased chance of internal bleeding, a well-known side effect of aspirin use.

The bottom line is that many women, especially those 65 and older, may benefit from taking low-dose aspirin every other day to prevent stroke. But it is important for women to weigh the risk and benefits of taking aspirin and to consult with their doctor.

Above all, women, like men, should adopt the well-proven approaches that reduce the risk of heart disease eating for heart health,
'"/>

Contact: NHBLI Communications Office
nhlbi_news@nhlbi.nih.gov
301 496-4236
NIH/National Heart, Lung, and Blood Institute
7-Mar-2005


Page: 1 2

Related medicine news :

1. Statement: Implantable medical identification chip
2. Statement from Barbara Alving of NHLBI on guidelines for cardiovascular disease prevention in women
3. Statement from Spondylitis Association of America
4. Statement by Dr. Colwell on Nobel Prizes in Science and NSF onnection
5. The CARDIA Study: Statement from Dr. Claude Lenfant, director, National Heart, Lung, and Blood Institute
6. Statement from Dr. Claude Lenfant, director, NHLBI and Dr. Phillip Gorden, director, NIDDK
7. Statement from Claude Lenfant, M.D., NHLBI Director, on Trends in Hypertension
8. Dental Researchers Retract Statement Indicating Hydrogen Peroxide May Be Cancer Promoter
9. Latest findings on genetic blood disorder Cooleys Anemia
10. Hard choices: Pitt researcher presents findings on when to accept organ transplants
11. Contrary to previous findings, smoking is detrimental to patients with Alzheimers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... practice partnerships through affiliations and de novo development, today announced Cumberland Skin ... , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s ... Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index surveys 140 of the ... began in 2006, Melbourne has consistently come in the top three of the index. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
Breaking Medicine Technology:
Cached News: